SCHEMBL2336799

SCHEMBL2336799

COC(=O)c1ccc(OCC2(O)CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CYP2D6 P10635 2/20 0.54
TSHR P16473 1/20 0.54
ALDH1A1 P00352 4/20 0.53
MAPT P10636 3/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.52
SSTR5 P35346 1/20 0.52
MAPK1 P28482 2/20 0.51
PKM P14618 1/20 0.51
KDM1A O60341 1/20 0.50
MAOB P27338 1/20 0.50
RAB9A P51151 1/20 0.50
FAAH O00519 1/20 0.48
CHRM4 P08173 1/20 0.48
NPFFR1 Q9GZQ6 1/20 0.48
NPFFR2 Q9Y5X5 1/20 0.48
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9209237 0.89 LMNA (0.55) MEN1KMT2AL3MBTL1CYP2D6TSHR
SCHEMBL2341863 0.88 SSTR5 (0.60) CYP2D6TSHRALDH1A1POLBSSTR5
SCHEMBL10345184 0.84 OPRL1 (0.56) MEN1KMT2ACYP2D6TSHRALDH1A1
Bromide SCHEMBL10345274 0.83 OPRL1 (0.55) MEN1KMT2ACYP2D6TSHRALDH1A1
SCHEMBL9212770 0.83 CHRM4 (0.51) CHRM4
SCHEMBL10345227 0.82 CCR3 (0.60) CYP2D6ALDH1A1POLBMAPK1RAB9A
SCHEMBL2345613 0.80 MEN1 (0.53) MEN1KMT2AL3MBTL1CYP2D6TSHR
SCHEMBL2342807 0.79 CYP3A4 (0.57) MEN1KMT2ACYP2D6TSHRALDH1A1
SCHEMBL6283441 0.78 FAAH (0.57) ALDH1A1MAPTLMNAFAAH
SCHEMBL5059977 0.78 ALDH1A1 (0.64) MEN1KMT2ATSHRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1568688-B1 THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT MOCHIDA PHARM CO LTD (JP) 2011-08-31 EP disclosed
US-7494987-B2 Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-02-24 US disclosed
US-7494987-B2 Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-02-24 US disclosed
US-7494987-B2 Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-02-24 US disclosed
US-20060040985-A1 Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
US-6956046-B2 4-hydroxypiperidine derivatives having analgesic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-18 US disclosed
EP-1568688-A1 THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-08-31 EP disclosed
US-20040176410-A1 4-hydroxpiperdine derivative with analgetic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-09-09 US disclosed
EP-1391452-A1 4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-02-25 EP disclosed
EP-0320032-B1 Pyridizinamine derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-01-18 EP disclosed
US-5231184-A Viricide intermediate JANSSEN PHARMACEUTICA N.V. (BE) 1993-07-27 US disclosed
US-5106973-A Viricide intermediates JANSSEN PHARMACEUTICA N.V. (BE) 1992-04-21 US disclosed
US-4992433-A Viricides JANSSEN PHARMACEUTICA N.V. (BE) 1991-02-12 US disclosed
EP-0320032-A1 Pyridizinamine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1989-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176410-A1 4-hydroxpiperdine derivative with analgetic activity HNMT, HDAC1, HDAC3 MEN1 3914/4885KMT2A 1783/4885L3MBTL1 4622/4885
US-20060040985-A1 Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient BRD7, RBBP7, NR0B1 MEN1 2763/4885KMT2A 2822/4885L3MBTL1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.